CAR T, car t cell
CAR T Cell therapy for refractory systemic lupus erythematosus in China
What is systemic lupus erythematosus? Systemic lupus erythematosus (SLE) is defined by an abnormal immune response, resulting in a highly varied clinical presentation that can potentially impact many systems and organs. Although ..
Zevorcabtagene autoleucel (Zevra-cel therapy) approved for R/R multiple myeloma
SHANGHAI, China, April 30, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ..
CAR T, CAR T cells, China
After amazing growth of CAR T-Cell therapy: what’s next?
The future of CAR T-cell therapy: an analysis of its rapid growth and expansion. Within the realm of contemporary medicine, CAR T-cell therapy emerges as an innovative and groundbreaking intervention, particularly for specific fo..
Abecma, Breyanzi, CARVYKTI, Kymriah, Tecartus, Yeskarta
Human-Based CAR T Cell Therapy: Breakthroughs and Challenges
Introduction In the domain of oncology, immunotherapy has emerged as a pioneering methodology, harnessing the body's immune system to combat malignant tumors. There are many immunotherapeutic approaches, but Chimeric Antigen Rece..
Understanding Cytokine Release Syndrome: Causes, Symptoms, and Treatment
Introduction Cytokine Release Syndrome (CRS) is an immune system overreaction triggered by therapies like immunotherapy or CAR-T cell treatment. It prompts an influx of cytokines, causing symptoms ranging from fever to potentiall..
CAR T, CAR T cells, CAR T Therapy, CAR-T treatment
Role of paramedics in the success of CAR T Cell therapy
Patients undergoing outpatient CAR T-cell therapy for cancer must be cared for by a multidisciplinary team that includes nurse coordinators, according to a poster presented at the 49th Annual Oncology Nursing Society Conference. ..
CAR T Cell therapy for AIDS related B-Cell malignancies
Introduction CAR T cell therapy, an innovative form of immunotherapy, has demonstrated exceptional efficacy in the treatment of specific tumors by leveraging the potency of a patient's own immune system. Recently, scientists have..
Understanding relations between MRD and CAR T-Cell therapy
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during treatment. Flow cytometry, polymerase chain reaction (PCR), or next-generati..
Orphan drug designation is given by FDA to CART T-Cell Therapy A2B530 for the treatment of colorectal cancer
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expr..
Revolutionizing Multiple Myeloma Treatment through CAR T-Cell Therapy in China
Feb 2024: China's pioneering efforts in creating breakthrough cancer therapeutics have gained traction with the introduction of chimeric antigen receptor (CAR)-engineered T-cell (CAR T) therapy for multiple myeloma, a devastatin..